롱리드 시퀀싱 시장 : 전략적 인사이트와 예측(2026-2035년)

The Long-Read Sequencing Market is growing at a CAGR of 14.3% from USD 2.51 billion in 2026 to USD 8.34 billion in 2035.

Long-read sequencing has emerged as a transformative genomic technology capable of reading significantly longer DNA and RNA fragments than conventional short-read sequencing methods. By preserving genomic context, these technologies enable accurate detection of structural variants, repeat expansions, gene fusions, and highly repetitive genomic regions that are difficult to characterize using traditional sequencing approaches. Growing applications in clinical genomics, oncology, infectious disease surveillance, agricultural genomics, and pharmaceutical research continue to accelerate adoption. Advances in single-molecule sequencing technologies, nanopore platforms, artificial intelligence-assisted data analysis, and declining sequencing costs are further expanding the commercial potential of long-read sequencing across research and clinical laboratories.

Market Drivers

Growing Demand for Structural Variant Detection

Structural genomic alterations play an important role in many inherited disorders, cancers, and neurological diseases. Long-read sequencing enables comprehensive identification of these complex genomic changes, driving increasing adoption in both research and clinical settings.

Expansion of Precision Medicine

Healthcare providers and research organizations are increasingly integrating comprehensive genomic profiling into personalized medicine initiatives. Long-read sequencing improves disease characterization, biomarker discovery, and treatment selection by providing higher-resolution genomic information.

Rising Rare Disease Research

Many rare genetic disorders involve repeat expansions, chromosomal rearrangements, and structural abnormalities that are difficult to detect using short-read sequencing. Long-read technologies are becoming valuable tools for improving diagnostic yield in rare disease investigations.

Continuous Technology Improvements

Ongoing advances in sequencing chemistry, read accuracy, throughput, and bioinformatics analysis continue improving workflow efficiency while supporting broader adoption across genomics laboratories.

Market Restraints

High Instrument Costs

Long-read sequencing platforms require significant capital investment, limiting adoption among smaller laboratories and resource-constrained healthcare institutions.

Complex Data Analysis

Long-read datasets require advanced computational infrastructure and specialized bioinformatics expertise, increasing operational complexity for laboratories.

Limited Clinical Standardization

Although clinical adoption is expanding, standardized analytical workflows and regulatory validation continue to evolve across different healthcare systems.

Market and Technology Insights

The global long-read sequencing market can be segmented by product & service, technology, application, end user, and geography.

By product & service, the market includes instruments, consumables & reagents, sequencing services, and bioinformatics & data analysis services. Consumables and reagents account for a significant portion of recurring market revenue due to their continuous use throughout sequencing workflows.

By technology, the market comprises Single-Molecule Real-Time (SMRT) sequencing and nanopore sequencing. Both technologies continue advancing in read accuracy, throughput, and scalability, enabling broader applications across research and clinical genomics.

By application, long-read sequencing supports human genomics research, rare disease diagnostics, oncology, infectious disease research, agricultural & plant genomics, and microbial genomics. Human genomics and rare disease research remain key application areas because comprehensive genome characterization increasingly relies on long-read technologies.

By end user, the market includes academic & research institutes, hospitals & diagnostic laboratories, pharmaceutical & biotechnology companies, and government & public health organizations. Academic research institutions continue representing major adopters owing to extensive genomics research and technology development activities.

Market Trends

The long-read sequencing market continues evolving through technological innovation.

Key trends include:

• Increasing adoption for structural variant analysis.
• Expansion of clinical genomics applications.
• Continuous improvements in sequencing accuracy.
• Integration of artificial intelligence into genomic analysis.
• Growing investment in precision medicine.
• Expansion of microbial and agricultural genomics.
• Increasing demand for advanced bioinformatics solutions.

Regional Insights

North America remains the largest market owing to strong investment in genomic research, advanced healthcare infrastructure, extensive precision medicine initiatives, and the presence of leading sequencing technology companies.

Europe maintains a significant market share through large-scale genomics programs, collaborative research networks, and increasing adoption of advanced sequencing technologies across clinical and academic institutions.

Asia-Pacific is expected to witness the fastest growth because of expanding biotechnology industries, increasing genomic research funding, improving healthcare infrastructure, and growing investments in precision medicine. China, Japan, South Korea, India, and Australia continue strengthening regional sequencing capabilities.

Latin America and the Middle East & Africa are gradually expanding sequencing capacity through research collaborations, public health genomics initiatives, and growing investment in molecular diagnostics.

Competitive Landscape

The market is characterized by continuous technological innovation and strategic partnerships among sequencing technology providers, bioinformatics companies, and life science organizations.

Major companies include Oxford Nanopore Technologies, Pacific Biosciences (PacBio), Illumina, Thermo Fisher Scientific, Roche, Revvity (PerkinElmer), QIAGEN, Agilent Technologies, 10x Genomics, and Element Biosciences. Companies continue investing in higher-throughput sequencing platforms, improved chemistry, AI-driven analysis software, and integrated workflow solutions to strengthen their competitive positions. Recent industry developments, including Roche's launch of its Axelios sequencing platform, highlight increasing competition within the long-read sequencing industry.

Future Outlook

The future of the long-read sequencing market will be driven by expanding clinical adoption, declining sequencing costs, improvements in read accuracy, and broader integration into precision medicine. Advances in nanopore sequencing, single-molecule technologies, cloud-based bioinformatics, and artificial intelligence are expected to improve genomic interpretation while enabling routine use across clinical diagnostics, oncology, rare disease testing, infectious disease surveillance, and population genomics.

Conclusion

The Global Long-Read Sequencing Market is expected to experience robust growth through 2035, supported by increasing demand for comprehensive genomic analysis, expanding precision medicine programs, and continuous advances in sequencing technology. Although high equipment costs, complex data analysis, and evolving clinical standards remain challenges, ongoing innovation in sequencing platforms, bioinformatics, and clinical genomics is expected to create significant opportunities for technology developers, healthcare providers, pharmaceutical companies, researchers, and investors.

Key Benefits of this Report

• Comprehensive assessment of the global long-read sequencing market.
• Detailed evaluation of sequencing technologies, applications, and emerging trends.
• Analysis of competitive strategies, technological innovation, and commercialization opportunities.
• Insights into precision medicine, structural variant detection, and bioinformatics developments.
• Valuable resource for sequencing technology providers, pharmaceutical companies, biotechnology firms, healthcare organizations, researchers, investors, and policymakers.

What Businesses Use Our Reports For

Technology assessment, product portfolio planning, competitive benchmarking, precision medicine strategy, investment analysis, partnership evaluation, research planning, commercialization strategy, regulatory planning, and long-term business decision-making.

Report Coverage

• Historical data from 2021 to 2025, Base Year 2026, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global long-read sequencing market by product & service, technology, application, end user, and geography
• Evaluation of market dynamics, technological innovation, competitive landscape, regulatory developments, and future growth opportunities
• Assessment of SMRT sequencing, nanopore sequencing, bioinformatics solutions, precision medicine, structural variant detection, clinical genomics, and commercialization strategies
• Analysis of instruments, consumables & reagents, sequencing services, bioinformatics & data analysis services, human genomics, rare disease diagnostics, oncology, infectious disease research, agricultural genomics, microbial genomics, and emerging long-read sequencing technologies through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Long-Read Sequencing Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast Analysis (2026-2035)
• 3.7 Clinical and Research Utility of Long-Read Sequencing
• 3.8 Evolution of Long-Read Sequencing Technologies
• 3.9 Genomic Research Ecosystem Overview
• 3.10 Sequencing Throughput and Testing Volume Analysis
• 3.11 Installed Base Analysis of Long-Read Sequencing Platforms
• 3.12 User Adoption Analysis
• 3.13 Structural Variant and Complex Genomics Testing Landscape

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape
• 5.4 Stakeholder Ecosystem Analysis
• 5.5 Long-Read Sequencing Infrastructure Analysis

6. Innovation Landscape

• 6.1 Emerging Long-Read Sequencing Technologies
• 6.2 Product Innovation Analysis
• 6.3 Clinical Trial Analysis Utilizing Long-Read Sequencing
• 6.4 Pipeline Analysis of Long-Read Sequencing-Based Diagnostic Solutions
• 6.5 AI Integration in Genomic Data Interpretation
• 6.6 Multi-Omics Integration with Long-Read Sequencing
• 6.7 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements
• 7.4 Genomic Data Privacy and Security Regulations

8. Long-Read Sequencing Market Landscape Analysis

• 8.1 Analysis by Product & Service Category
• 8.2 Analysis by Sequencing Technology
• 8.3 Analysis by Application
• 8.4 Analysis by End User Environment
• 8.5 Analysis by Sample Type
• 8.6 Analysis by Workflow

9. Long-Read Sequencing Market Segment Analysis (2021-2035)

• 9.1 By Product & Service
  • 9.1.1 Instruments
  • 9.1.2 Consumables & Reagents
  • 9.1.3 Sequencing Services
  • 9.1.4 Bioinformatics & Data Analysis Services
• 9.2 By Technology
  • 9.2.1 Single-Molecule Real-Time (SMRT) Sequencing
  • 9.2.2 Nanopore Sequencing
• 9.3 By Application
  • 9.3.1 Human Genomics Research
  • 9.3.2 Rare Disease Diagnostics
  • 9.3.3 Oncology
  • 9.3.4 Infectious Disease Research
  • 9.3.5 Agricultural & Plant Genomics
  • 9.3.6 Microbial Genomics
• 9.4 By End User
  • 9.4.1 Academic & Research Institutes
  • 9.4.2 Hospitals & Diagnostic Laboratories
  • 9.4.3 Pharmaceutical & Biotechnology Companies
  • 9.4.4 Government & Public Health Organizations

10. Long-Read Sequencing Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Long-Read Sequencing Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Netherlands
• 11.7 China
• 11.8 Japan
• 11.9 South Korea
• 11.10 India
• 11.11 Australia
• 11.12 Singapore
• 11.13 Brazil
• 11.14 Saudi Arabia
• 11.15 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches
• 12.5 Competitive Benchmarking Analysis

13. Company Profiles

• 13.1 Pacific Biosciences of California, Inc.
• 13.2 Oxford Nanopore Technologies plc
• 13.3 Illumina, Inc.
• 13.4 Thermo Fisher Scientific Inc.
• 13.5 QIAGEN N.V.
• 13.6 F. Hoffmann-La Roche Ltd.
• 13.7 Agilent Technologies, Inc.
• 13.8 Revvity, Inc.
• 13.9 BGI Genomics Co., Ltd.
• 13.10 Element Biosciences, Inc.
• 13.11 Singular Genomics Systems, Inc.
• 13.12 Bio-Rad Laboratories, Inc.
• 13.13 GeneDx Holdings Corp.
• 13.14 SOPHiA GENETICS SA
• 13.15 Fabric Genomics, Inc.

14. Long-Read Sequencing Market Commercial Forecast Analysis

• 14.1 Instruments Forecast
• 14.2 Consumables & Reagents Forecast
• 14.3 Sequencing Services Forecast
• 14.4 Bioinformatics & Data Analysis Services Forecast
• 14.5 SMRT Sequencing Forecast
• 14.6 Nanopore Sequencing Forecast
• 14.7 Human Genomics Research Forecast
• 14.8 Rare Disease Diagnostics Forecast
• 14.9 Oncology Applications Forecast

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments
• 15.4 Genomics Infrastructure Investments
• 15.5 Strategic Financing Activities

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends
• 16.3 Evolution of Long-Read Sequencing in Clinical Diagnostics
• 16.4 Future of Structural Variant Analysis and Genome Assembly
• 16.5 Impact of AI-Driven Genomics on Long-Read Sequencing Adoption
• 16.6 Long-Term Market Outlook (2035)